Uromitexan 400 Mg Injection 400 mg Injection
PDF Leaflet Revision Date: 28 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Reduces urinary toxicity from oxazaphosphorines.
Dosage (summary)
IV injection of 20% of oxazaphosphorine dose at 0, 4, and 8 hours.
Special Populations
- Elderly patients
- Paediatric patients (<16 years)
Pregnancy & Breastfeeding
Not established; avoid in pregnancy and lactation.
Key Drug Interactions
- Incompatible with cisplatin, carboplatin, nitrogen mustard
- Inactivates epirubicin
Contraindications
- Hypersensitivity to UROMITEXAN or thiol compounds
Common side effects
- Headache
- Infusion site reactions
- Abdominal pain
- Light-headedness
- Nausea
Counselling Points
- Monitor for hypersensitivity reactions
- Maintain adequate hydration
- Inspect for particulate matter before use
Serious warnings
- Potential for severe hypersensitivity reactions
- Does not prevent all adverse effects of oxazaphosphorines
Important Disclaimer
The Uromitexan 400 Mg Injection 400 mg Injection professional information leaflet below is the property of Baxter Healthcare South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
